Anavex Life Sciences
Symbol: AVXL (NASDAQ)
Company Description:
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
- Today's Open: $8.68
- Today's High: $8.715
- Today's Low: $8.402
- Today's Volume: 1.92M
- Yesterday Close: $8.67
- Yesterday High: $8.9307
- Yesterday Low: $8.55
- Yesterday Volume: 1.22M
- Last Min Volume: 50
- Last Min High: $8.5
- Last Min Low: $8.5
- Last Min VWAP: $8.5
- Name: Anavex Life Sciences
- Website: https://www.anavex.com
- Listed Date: 2006-08-02
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001314052
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $726.66M
- Round Lot: 100
- Outstanding Shares: 85.89M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-12 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-12 | 10-Q | View |
| 2025-07-28 | 8-K | View |
| 2025-07-25 | 424B5 | View |
| 2025-07-23 | EFFECT | View |
| 2025-07-21 | CORRESP | View |
| 2025-07-21 | UPLOAD | View |
| 2025-07-14 | S-3 | View |
| 2025-07-03 | 8-K | View |
| 2025-06-13 | 8-K | View |
| 2025-06-09 | 4 | View |
| 2025-05-13 | 10-Q | View |
| 2025-04-30 | 4 | View |
| 2025-04-30 | 4 | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
| 2025-04-25 | DEF 14A | View |
| 2025-04-02 | 4 | View |